Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001830 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for Haemophilia A.
A Phase 1 study of Hemophilia A, sponsored by University College, London.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT03001830 is a Phase 1 study of Hemophilia A that is active but no longer recruiting, run by University College, London. The registered enrollment target is 14 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03001830, a Phase 1 study of Hemophilia A, is active but no longer recruiting, sponsored by University College, London.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A
Conditions Studied
Interventions
- BIOLOGICAL AAV2/8-HLP-FVIII-V3
Study Locations (4)
Idaho
- St. Luke'S Regional Medical Center, Ltd - Boise
Kentucky
- University of Kentucky - Lexington
Tennessee
- St Jude's Children's Research Hospital - Memphis
Other
- Royal Free Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03001830
The ClinicalTrials.gov registry entry for NCT03001830 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower). The listed sponsor is University College, London, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which AAV2/8-HLP-FVIII-V3 is the first listed.
NCT03001830 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Idaho, Kentucky, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03001830 about?
NCT03001830 is a clinical study titled "Gene Therapy for Haemophilia A.". The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A
What is the current status of trial NCT03001830?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-06-14. Estimated completion is 2029-12.
What conditions does trial NCT03001830 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT03001830?
The interventions under investigation include: AAV2/8-HLP-FVIII-V3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03001830?
This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03001830 being conducted?
This trial has 4 study locations across Idaho, Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.